CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +7.7% ·
share flow +4.7% ·
net new positions +7.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +7 | 95.71M | $8.15B | +10 | −2 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | — | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | — |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | — | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | — |
| Q2 2024 | 11 | — | 17.42M | $943.61M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.99M | +1.3% | $321.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 6.09M | -1.3% | $244.56M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 2.94M | +3.4% | $118.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 2.94M | +3.4% | $118.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Marshall Wace ✦ | 2.03M | -5.8% | $81.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 13 | Marshall Wace ✦ | 2.03M | -5.8% | $81.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 1.99M | -24.0% | $80.14M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 1.99M | -24.0% | $80.14M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 1.72M | +914.0% | $69.25M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 17 | Norges Bank ✦ (passive) | 1.18M | +18.9% | $47.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1.15M | -16.1% | $46.24M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 1.15M | -16.1% | $46.24M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 793.46K | +28.7% | $31.89M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 287.90K | +469.8% | $11.57M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Renaissance Technologies ✦ | 120.67K | -37.2% | $4.85M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 44.16K | -51.6% | $1.77M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 19.99K | -39.9% | $803,559 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 19.99K | -39.9% | $803,559 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 19.99K | -39.9% | $803,559 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 19.99K | -39.9% | $803,559 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 19.99K | -39.9% | $803,559 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 29 | D. E. Shaw & Co. ✦ | 13.30K | New | $534,607 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $534,607 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 437 holders, 145.17M shares, $8.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.50K sh · $265,370
Officer, Director · 7.50K sh · $575,700
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology